Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

William Cheung

2 papers in the library · 12 citations · publishing 2025-2026

Papers

The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.

Journal of Affective Disorders August 1, 2025 Morgan C H Cheng, Christine E. Dri, Hana Ballum et al. 12 citations

Ketamine and esketamine produce rapid antidepressant effects in major depressive disorder and treatment-resistant depression, but their impact on patient-reported quality of life has been unclear. A systematic review of five studies found that both agents improve quality of life measures on scales such as the WHOQOL-BREF, Assessment of Quality of Life 8D, and EuroQol-5 Dimension-5 Layers, with statistically significant results. However, the studies had an overall moderate risk of bias and varied in the quality-of-life scales used and study duration. Further research should examine effects on specific quality-of-life domains.

DOI: 10.1016/j.jad.2025.04.119 (opens in new tab) Full text (opens in new tab) Esketamine Patient-reported outcomes Quality of life Depression therapy +4

The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.

Journal of Psychiatric Research June 1, 2026 Kyle Valentino, Hana Ballum, William Cheung et al.

About 80% of people with major depressive disorder (MDD) report insomnia. This systematic review examined how glutamatergic modulators, especially ketamine, affect sleep in preclinical and clinical studies. Preclinical work showed ketamine alters EEG delta power during NREM sleep and normalizes clock suppressor gene expression, while esketamine enhances delta power but arketamine does not. mGlu2/3 activators reduce REM sleep. Clinical studies indicate that improved sleep can mediate ketamine's antidepressant effects in MDD. The authors suggest that sleep-related mechanisms are potential targets for depression treatment.

DOI: 10.1016/j.jpsychires.2026.02.011 (opens in new tab) Full text (opens in new tab) Depression Early morning awakening Gamma-aminobutyric acid gaba Glutamate +2